Altretamine
As of the edition of 20 October 2026, Altretamine is a small molecule: marketed, first approved in 1979 (FR).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1990
- Kind
- Small molecule
- Brand name
- Hexalen
- First approved
- 22 January 1979 (FR)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Eisai; 2 holders in all
- Registered trials
- 1, 0 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| All trials | 1 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Eisai | Applicant | 1990 to now |